Inhibition of the cytokine-mediated inducible nitric oxide synthase expression in rat insulinoma cells by phenyl N-tert-butylnitrone

Nitric Oxide - Biology and Chemistry

Volumn 4, Issue 2, 2000, Pages 157-167

  Tabatabaie, Tahereh ^a   Graham, Kaarem L ^a   Vasquez, Angelica M ^a   Floyd, Robert A ^a   Kotake, Yashige ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Free radicals; Inducible nitric oxide synthase; Nitric oxide; Proinflammatory cytokines; Spin trapping agent

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; N TERT BUTYL ALPHA PHENYLNITRONE; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOBLOTTING; INSULIN DEPENDENT DIABETES MELLITUS; INSULINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALIA;

EID: 0034035918     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1006/niox.2000.0281     Document Type: Article

References (52)

1. Pukel C., Baquerizo H., Rabinovitch A. Destruction of rat islet cell monolayers by cytokines: Synergistic interactions of interferon-γ, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes. 37:1988;133-136.
2. Mandrup-Poulsen T., Bendtzen K., Dinareeo C. A., Nerup J. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic β-cell cytotoxicity. J. Immunol. 139:1987;4077-4082.
3. Mandrup-Poulsen T., Bendtzen K., Nielsen J. H., Bendixen G., Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 40:1985;424-429.
4. Rabinovitch A. Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev. 1:1993;215-240.
5. Campbell I. L., Kay T. W. H., Oxbrow L., Harrison L. C. Essential role for interferon-γ and Interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87:1991;739-742.
6. Southern D., Schulster D., Green I. C. Inhibition of insulin secretion by interleukin-1 and tumor necrosis factor-α via an L-arginine-dependent nitric oxide generation mechanism. FEBS Lett. 276:1990;42-44.
7. Reimers J. I., Bjerre U., Mandrup-Poulsen T., Nerup J. Interleukin 1β induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. Cytokine. 6:1994;512-520.
8. Corbett J. A., Kwon G., Misko T. P., Rodi C. P., McDaniel M. L. Tyrosine kinase involvement in IL-1β-induced expression of iNOS by β-cells purified from islets of Langerhans. Am. J. Physiol. 267:1994;C48-C54.
9. Corbett J. A., McDaniel M. L. Intraislet release of interleukin 1 inhibits β cell function by expression of inducible nitric oxide synthase. J. Exp. Med. 181:1995;559-568.
10. Tabatabaie T., Kotake Y., Wallis G., Jacob J. M., Floyd R. A. Spin trapping agent phenyl N-tert-butylnitrone protects against the onset of drug-induced insulin-dependent diabetes mellitus. FEBS Lett. 407:1997;148-152.
11. Janzen E. G. Spin trapping. Acc. Chem. Res. 4:1971;31-37.
12. Carney J. M., Floyd R. A. Protection against oxidative damage to CNS by α-phenyl-tert-butylnitrone (PBN) and other spin trapping agents: A novel series of nonlipid free radical scavengers. J. Mol. Neurosci. 3:1991;47-57.
13. Zhao Q., Pahlmark K., Smith M-I., Siesjo B. K. Delayed treatment with the spin trap α-phenyl-N-tert-butylnitrone (PBN) reduces infarct size following transient middle cerebral artery occlusion in rats. Acta Physiol. Scand. 152:1994;349-350.
14. Cao X., Phillis J. α-phenyl-tert-butyl-nitrone reduces cortical infarct and edema in rats subjected to focal ischemia. Brain Res. 644:1994;267-272.
15. Barth A., Barth L., Newell D. W. Combination therapy with MK-801 and α-phenyl-tert-butyl-nitrone enhances protection against ischemic neuronal damage in organotypic hippocampal slice cultures. Exp. Neurol. 141:1996;330-336.
16. Pahlmark K., Siesjö B. K. Effects of spin trap α-phenyl-N-tert-butylnitrone (PBN) in transient forebrain ischemia in the rat. Acta Physiol. Scand. 157:1996;41-51.
17. Tabatabaie T., Stewart C. A., Pye Q. T., Kotake Y., Floyd R. A. In vivo trapping of nitric oxide in the brain of rat neonates treated with HIV-1 envelope protein gp-120: Protective effects of α-phenyl-N-tert-butylnitrone. Biochem. Biophys. Res. Commun. 221:1996;386-390.
18. Novelli G. P., Angiolini P., Gonsales G., Lippi R., Tani R. Anti-shock action of phenyl t-butyl nitrone, a spin trapper. Novelli G. P., Ursini F. Oxygen Free Radicals in Shock. 1986;119-124 Karger, Basle.
19. Hamburger S. A., McCay P. B. Endotoxin-induced mortality in rats is reduced by nitrones. Circ. Shock. 29:1989;329-334.
20. Harkins J. D., Carney J. M., Meier M., Leak S. C., Tobin T. Effect of α-phenyl-tert-butylnitrone on endotoxin toxemia in horses. Vet. Hum. Toxicol. 39:1997;268-271.
21. Carney J. M., Starke-Reed P., Oliver C., Landum R., Cheng M., Wu J., Floyd R. A. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-α-phenylnitrone. Proc. Natl. Acad. Sci. USA. 88:1981;3633-3636.
22. Sack C. A., Socci D. J., Crandall B. M., Arendash G. W. Antioxidant treatment with phenyl-α-tert-butyl nitrone (PBN) improves the cognitive performance and survival of aging rats. Neurosci. Lett. 205:1996;181-184.
23. Edamatsu R., Mori A., Packer L. The spin trap N-tert-α-phenyl butyl nitrone prolongs the lifespan of the senescence accelerated mouse. Biochem. Biophys. Res. Commun. 211:1995;847-849.
24. Saito K., Yoshioka H., Cutler R. G. A spin trap, N-tert-butyl-alpha-phenylnitrone extends the lifespan of mice. Biosci. Biotechnol. Biochem. 62:1998;792-794.
25. Miyajima T., Kotake Y. Spin trapping agent, phenyl N-tert-butylnitrone (PBN) inhibits induction of nitric oxide synthase in endotoxin-induced shock in mice. Biochem. Biophys. Res. Commun. 215:1995;114-121.
26. Miyajima T., Kotake Y. Optimal time and dosage of phenyl N-tert-butylnitrone (PBN) for the inhibition of nitric oxide synthase induction in mice. Free Radical Biol. Med. 22:1997;463-470.
27. 15N] nitrate in biological fluids. Anal. Biochem. 126:1982;131-138.
28. Pesce A., McKay R. H., Stolzenbach F., Cahn R. D., Kaplan N. O. The comparative enzymology of lactic dehydrogenases. J. Biol. Chem. 239:1964;1753-1761.
29. Kotake Y. Continuous and quantitative monitoring of rate of cellular nitric oxide generation. Methods Enzymol. 268:1996;222-229.
30. Hill H. D., Straka J. G. Protein determination using bicinchoninic acid in the presence of sulfhydryl reagents. Anal. Biochem. 170:1988;203-208.
31. Corbett J. A., Tilton R. G., Chang K., Hasan K., Ido Y., Wang J., Sweetland M. A., Lancaster J. R. Jr., Williamson J. R., McDaniel M. L. Aminoguanidine, a novel inhibitor of nitric oxide formation prevents diabetic vascular dysfunction. Diabetes. 41:1992;552-556.
32. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horizons. 3:1995;2-32.
33. Packer L., Tritschler H. J., Wessel K. Neuroprotection by the metabolic antioxidant α-lipoic acid. Free Radical Biol. Med. 22:1997;359-378.
34. Kwon G., Corbett J. A., Rodi C. P., Sullivan P., McDaniel M. L. Interleukin-1 β-induced nitric oxide synthase expression by rat pancreatic β-cells: Evidence for the involvement of nuclear factor κB in the signaling mechanism. Endocrinology. 136:1995;4790-4795.
35. Sang H., Wallis G. L., Stewart C. A., Kotake Y. Expression of cytokines and activation of transcription factors in lipopolysaccharide administered rats and their inhibition by phenyl-N-tert-butylnitrone (PBN). Arch. Biochem. Biophys. 363:1999;341-348.
36. Sandberg J.-O., Anderson A., Eizirik D. L., Sandler S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem. Biophys. Res. Commun. 202:1994;543-548.
37. Cockfield S. M., Ramassar V., Urmson J., Halloran P. F. Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cell to release IFN-γ J. Immunol. 142:1989;1120-1128.
38. Lukic M. L., Stosic-Gruijcic S., Ostojic N., Chan W. L., Liew F. Y. Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin in mice. Biochem. Biophys. Res. Commun. 178:1991;913-920.
39. Niemann A., Bjorklund A., Eizirik D. L. Studies on molecular regulation of inducible form of nitric oxide synthase (iNOS) in insulin-producing cells. Mol. Cell. Endocrinol. 106:1994;151-155.
40. Dimmler S., Ankarcrona M., Nicotera P., Brune B. Exogenous nitric oxide (NO) generation or IL-1β induced intracellular NO production stimulates inhibitory auto-ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase in RINm5F cells. J. Immunol. 150:1993;2964-2971.
41. Leib S. L., Kim Y. S., Chow L. L., Sheldon R. A., Täuber M. G. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J. Clin. Invest. 98:1996;2632-2639.
42. Parman T., Wiley M., Wells P. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Med. 5:1999;582-585.
43. Screck R., Albermann K., Baeuerle P. A. Nuclear factor κB: An oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radical Res. Commun. 17:1992;221-237.
44. Wu K. K. Inducible cyclooxygenase and nitric oxide synthase. Adv. Pharmacol. 33:1995;179-207.
45. Bedoya F. J., Flodström M., Eizirik D. L. Pyrrolidine dithiocarbamate prevents IL-1 induced nitric oxide synthase mRNA, but not superoxide dismutase, mRNA, in insulin producing cells. Biochem. Biophys. Res. Commun. 210:1995;816-822.
46. Conner E. M., Grisham M. B. Inflammation, free radicals, and antioxidants. Nutrition. 12:1996;274-277.
47. Lander H. M. An essential role for free radicals and derived species in signal transduction. FASEB J. 11:1997;118-124.
48. Pogrebniak H. W., Merino M. J., Hahn S. N., Mitchell J. B., Pass H. J. Spin trap salvage from endotoxemia: The role of cytokine down-regulation. Surgery. 112:1992;130-139.
49. Thomas C. E., Ku G., Kalyanaraman B. Nitrone spin trap lipophilicity as a determinant for inhibition of low density lipoprotein oxidation and activation of IL-1β release from human monocytes. J. Lipid Res. 35:1994;610-619.
50. Kotake Y., Sang H., Miyajima T., Wallis G. L. Inhibition of NFκB, iNOS mRNA, COX2 mRNA, and COX catalytic activity by phenyl-N-tert-butylnitrone (PBN). Biochim. Biophys. Acta. 1448:1998;77-84.
51. McDaniel M. A., Kwon G., Hill J. R., Marshall C. A., Corbett J. R. Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. 211:1996;24-32.
52. Krönke K-D., Kolb-bachofen V., Berschick B., Burkart V., Kolb H. Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem. Biophys. Res. Commun. 175:1991;752-758.